The impact of carnosine on biological ageing - A geroscience approach.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing biological mechanisms and potential geroprotective properties without systematic methodology.
PubMed 39153379 · doi:10.1016/j.maturitas.2024.108091
What was done
This paper presents a narrative review summarizing the mechanistic evidence for carnosine (a dipeptide of beta-alanine and L-histidine) as a potential geroprotector targeting hallmarks of biological ageing, including oxidative stress, genomic instability, inflammation, and telomere attrition.
What was found
The abstract provides no quantitative data or specific numerical endpoints. It describes carnosine as possessing antioxidative, anti-inflammatory, and anti-glycating properties, with potential therapeutic applications for cognitive health, muscle function, and exercise performance in the context of healthy ageing.
Why it matters
It highlights carnosine alongside other candidate geroprotectors within a geroscience framework, summarizing its proposed multi-system actions across age-related decline.
Limits
The abstract describes a broad narrative overview rather than a systematic review or clinical trial; no study counts, sample sizes, or quantitative outcome metrics are reported. Human clinical efficacy, optimal dosing, and direct longevity outcomes are not established from this summary.
Cited by
- context A 2024 trial found that carnosine acts as a geroprotector via the NRF2 pathway and provides direct free radical scavenging and anti-inflammatory effects.